Rachna Khosla Biography and Net Worth

Senior Vice President, Business Development of Amgen

Rachna Khosla joined Amgen in 2013 and was named Senior Vice President, Business Development in September 2021. She is responsible for all business development activities across Amgen, including mergers and acquisitions and licensing/collaborations, search and evaluation, alliance management, and Amgen Ventures. Prior to this role, Khosla served as Vice President, Business Development, responsible for mergers and acquisitions, licensing, and corporate development activities, and prior to this served as Executive Director, Corporate Development. Khosla joined Amgen in 2013 as Corporate Development Director.

Prior to Amgen, Khosla was Director at Lazard Ltd. responsible for healthcare mergers and acquisitions. Before joining Lazard, Khosla had various roles at Credit Suisse Healthcare M&A, Sanofi Aventis, Aventis Capital, J.P. Morgan Chase & Co. and Salomon Brothers, Inc.

Khosla holds a BA degree from Barnard College, Columbia University and an MBA from Columbia Business School.

What is Rachna Khosla's net worth?: The estimated net worth of Rachna Khosla is at least $2.41 million as of November 12th, 2025. Ms. Khosla owns 7,082 shares of Amgen stock worth more than $2,409,013 as of December 5th. This net worth approximation does not reflect any other assets that Ms. Khosla may own. Learn More about Rachna Khosla's net worth.
How do I contact Rachna Khosla?: The corporate mailing address for Ms. Khosla and other Amgen executives is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. Amgen can also be reached via phone at (805) 447-1000 and via email at [email protected]. Learn More on Rachna Khosla's contact information.
Has Rachna Khosla been buying or selling shares of Amgen?: During the last ninety days, Rachna Khosla has sold $299,253.60 of Amgen stock. Most recently, Rachna Khosla sold 890 shares of the business's stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a transaction totalling $299,253.60. Following the completion of the sale, the senior vice president now directly owns 7,082 shares of the company's stock, valued at $2,381,251.68. Learn More on Rachna Khosla's trading history.
Who are Amgen's active insiders?: Amgen's insider roster includes Robert Bradway (Chairman & Chief Executive Officer), Robert Eckert (Director), Murdo Gordon (EVP), Jonathan Graham (EVP), Peter Griffith (Exec. VP & CFO ), Nancy Grygiel (SVP), Nancy Grygiel (SVP), Rachna Khosla (Senior Vice President, Business Development), David Reese (Executive Vice President and Chief Technology Officer), Ronald Sugar (Director), Ronald Sugar (Director), and R Williams (Director). Learn More on Amgen's active insiders.
Are insiders buying or selling shares of Amgen?: During the last year, insiders at the medical research company sold shares 10 times. They sold a total of 83,016 shares worth more than $25,130,107.38. The most recent insider tranaction occured on November, 20th when SVP Nancy A Grygiel sold 3,139 shares worth more than $1,058,659.14. Insiders at Amgen own 0.8% of the company. Learn More about insider trades at Amgen.
Information on this page was last updated on 11/20/2025.

Rachna Khosla Insider Trading History at Amgen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/12/2025	Sell	890	$336.24	$299,253.60	7,082
6/5/2025	Sell	1,500	$289.68	$434,520.00	8,162

Rachna Khosla Buying and Selling Activity at Amgen

Amgen Company Overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Today's Range

Now: $340.16

$338.94

$346.33

50 Day Range

MA: $312.27

$272.98

$345.42

2 Week Range

Now: $340.16

$253.30

$346.38

Volume

3,695,576 shs

Average Volume

2,720,721 shs

Market Capitalization

$183.17 billion

P/E Ratio

26.29

Dividend Yield

2.76%

Beta

0.45